28-Mar-2024
Affimed Therapeutics’ Optimistic Clinical Outlook
TipRanks (Thu, 28-Mar 9:27 PM ET)
Affimed GAAP EPS of -€7.09, revenue of €8.28M
Seeking Alpha News (Thu, 28-Mar 6:36 AM ET)
Affimed Reports 2023 Financial Results and Operational Progress
Globe Newswire (Thu, 28-Mar 6:30 AM ET)
Notable earnings before Thursday's open
Seeking Alpha News (Wed, 27-Mar 9:11 AM ET)
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
Globe Newswire (Thu, 21-Mar 6:30 AM ET)
Affimed Announces 1-for-10 Reverse Stock Split
Globe Newswire (Wed, 6-Mar 6:30 AM ET)
Globe Newswire (Mon, 8-Jan 4:05 PM ET)
Affimed Announces Leadership Change and Organizational Restructuring
Globe Newswire (Mon, 8-Jan 8:00 AM ET)
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
Globe Newswire (Wed, 3-Jan 6:30 AM ET)
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.
Affimed N.V. trades on the NASDAQ stock market under the symbol AFMD.
As of March 28, 2024, AFMD stock price declined to $5.30 with 79,448 million shares trading.
AFMD has a beta of 2.60, meaning it tends to be more sensitive to market movements. AFMD has a correlation of 0.12 to the broad based SPY ETF.
AFMD has a market cap of $79.15 million. This is considered a Micro Cap stock.
Last quarter Affimed N.V. reported $2 million in Revenue and -$1.70 earnings per share. This beat revenue expectation by $126,000 and exceeded earnings estimates by $.30.
In the last 3 years, AFMD stock traded as high as $117.40 and as low as $2.24.
The top ETF exchange traded funds that AFMD belongs to (by Net Assets): SPDW, FESM, GWX.
AFMD stock has underperformed the market in the last year with a return of -23.1%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AFMD shares. However, AFMD has outperformed the market in the last 3 month and 2 week periods, returning +12.2% and +10.6%, while SPY returned +10.1% and +1.7%, respectively. This indicates AFMD has been having a stronger performance recently.
AFMD support price is $4.91 and resistance is $5.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AFMD stock will trade within this expected range on the day.